CATNAP

Conditions: Clinical Diagnosis of Narcolepsy I or II

Type of Research: Observational
Principal Investigator: Michael Strunc MD
Primary Study Coordinator: Ashley Vasko BS

Study Specifications: Narcolepsy is a lifelong, debilitating neurological disorder, clinically characterized by a pentad of symptoms including excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic hallucinations, and disrupted nighttime sleep. There is little information in the literature regarding pediatric narcolepsy. CATNAP is an observational studying aiming to study the natural history, practices, and outcomes of pediatric narcolepsy.

Point of Contact for the Study: Ashley Vasko BS
Email: Ashley.Vasko@chkd.org
Phone: (757) 668-7176

SUVEN-G3031

Conditions: Narcolepsy I and II with impressive MSLT, MWT, and PSG scores.

Type of Research: Interventional
Principal Investigator: Michael Strunc, MD
Primary Study Coordinator: Erin McAndrews

Study Specifications: Narcolepsy is a long-term neurological disorder that specifically affects the regulation of sleep-wake cycles. SUVN-G3031 is a selective histamine that was developed for the treatment of narcolepsy. SUVEN aims to enroll patients over the age of 18 to be involved in this phase II trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4mg doses of SUVN-G3031.

Point of Contact for the Study: Erin McAndrews LPN
Email:Erin.McAndrews@chkd.org
Phone: (757) 668-6896